Cellectar 
Welcome,         Profile    Billing    Logout  
 3 Products   32 Diseases  3 Products   4 Trials   331 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Molixan (glutathione/inosine) / Cellectar
NCT04780672: Clinical Study in the Treatment of Patients With COVID-19

Recruiting
3
330
RoW
Molixan, Inosine glycyl-cysteinyl-glutamate disodium, Placebo, Sodium chloride
Pharma VAM
COVID-19
05/22
09/22
iopofosine I-131 (CLR 131) / Cellectar
CLOVER-WaM, NCT02952508 / 2020-005297-10: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

Active, not recruiting
2
120
Europe, US, RoW
Iopofosine I 131 single dose, I-131-CLR1404, CLR 131, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
Cellectar Biosciences, Inc.
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
12/25
12/26
NCT02278315: Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Completed
1
31
US
I-131-CLR1404, 131I-CLR1404, 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine, CLR 131, dexamethasone, Decadron
Cellectar Biosciences, Inc.
Multiple Myeloma
12/20
08/22
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
12/25
12/26
NCT04105543: CLR 131 Combined With Radiation for Head and Neck Cancer

Completed
1
12
US
CLR 131, I-131-CLR1404
University of Wisconsin, Madison, National Institute of Dental and Craniofacial Research (NIDCR), Cellectar Biosciences, Inc.
Head and Neck Cancer
09/22
02/24
NCT05610891: Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Active, not recruiting
1
50
Canada, US
CLR 131, iopofosine I 131
Cellectar Biosciences, Inc., National Cancer Institute (NCI)
High-Grade Glioma
05/26
09/26
CLR 1602-PTX / Cellectar
No trials found
CLR 125 / Cellectar
No trials found
CLR 1601-PTX / Cellectar
No trials found
phospholipid ether-paclitaxel conjugate (CLR 1603-PTX) / Cellectar
No trials found
CLR 1900 Series / Cellectar
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Molixan (glutathione/inosine) / Cellectar
NCT04780672: Clinical Study in the Treatment of Patients With COVID-19

Recruiting
3
330
RoW
Molixan, Inosine glycyl-cysteinyl-glutamate disodium, Placebo, Sodium chloride
Pharma VAM
COVID-19
05/22
09/22
iopofosine I-131 (CLR 131) / Cellectar
CLOVER-WaM, NCT02952508 / 2020-005297-10: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

Active, not recruiting
2
120
Europe, US, RoW
Iopofosine I 131 single dose, I-131-CLR1404, CLR 131, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
Cellectar Biosciences, Inc.
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
12/25
12/26
NCT02278315: Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Completed
1
31
US
I-131-CLR1404, 131I-CLR1404, 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine, CLR 131, dexamethasone, Decadron
Cellectar Biosciences, Inc.
Multiple Myeloma
12/20
08/22
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
12/25
12/26
NCT04105543: CLR 131 Combined With Radiation for Head and Neck Cancer

Completed
1
12
US
CLR 131, I-131-CLR1404
University of Wisconsin, Madison, National Institute of Dental and Craniofacial Research (NIDCR), Cellectar Biosciences, Inc.
Head and Neck Cancer
09/22
02/24
NCT05610891: Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Active, not recruiting
1
50
Canada, US
CLR 131, iopofosine I 131
Cellectar Biosciences, Inc., National Cancer Institute (NCI)
High-Grade Glioma
05/26
09/26
CLR 1602-PTX / Cellectar
No trials found
CLR 125 / Cellectar
No trials found
CLR 1601-PTX / Cellectar
No trials found
phospholipid ether-paclitaxel conjugate (CLR 1603-PTX) / Cellectar
No trials found
CLR 1900 Series / Cellectar
No trials found

Download Options